Annexon Biosciences, based in Brisbane, CA, is a biotechnology company that focuses on developing innovative therapies for autoimmune, neurodegenerative, and ophthalmic diseases. Led by a team of passionate experts, including co-founder Dr. Ben Barres, Annexon is dedicated to targeting C1q, the initiating molecule of the classical complement pathway, to block damaging components of the immune system and provide transformative treatments for patients suffering from complement-driven diseases.
With a strong pipeline of early complement inhibitors, Annexon aims to unlock the next generation of complement therapies, addressing diseases affecting the body, brain, and eye. Committed to scientific excellence, Annexon's research is centered around neuron-glial interactions in the central nervous system, offering promising solutions for devastating diseases. As a leading biotech company, Annexon is poised to make significant advancements in the field of complement-driven therapies.
Generated from the website